Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1998-6-30
|
| pubmed:abstractText |
In a prospective trial conducted by the Gruppo Onco Urologico Piemontese, newly diagnosed prostate cancer patients with bone metastases were randomized to receive goserelin (3.6 mg subcutaneously every 4 weeks) or goserelin plus mitomycin at 14 mg/m2 i.v. every 6 weeks. Treatment was planned to be continued until progression. The study was interrupted because of inadequate accrual rate when 63 patients had been recruited. A long-term follow-up (median, 47 months), performed to counterbalance the limited number of patients included, revealed no difference in time to progression and overall survival between the study treatments. However, 56.5% of assessable patients allocated to the chemotherapy arm presented a > or =90% reduction of prostate-specific antigen levels compared with 36.3% in the goserelin group, and previously elevated levels normalized in 73.9% versus 45.4%. Non-progressing patients received 5-7 cycles of mitomycin C with acceptable toxicity, but the cytotoxic treatment was interrupted early in all cases within the first year due to cumulative myelotoxicity. In conclusion, the results, although inconclusive, fail to support a clear advantage in terms of cost/benefit of chemotherapy plus hormone therapy over hormone treatment alone in advanced prostate cancer with bone involvement.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibiotics, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal,
http://linkedlifedata.com/resource/pubmed/chemical/Goserelin,
http://linkedlifedata.com/resource/pubmed/chemical/Mitomycin,
http://linkedlifedata.com/resource/pubmed/chemical/Prostate-Specific Antigen
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0300-8916
|
| pubmed:author |
pubmed-author:BerrutiAA,
pubmed-author:BertettoOO,
pubmed-author:BummaCC,
pubmed-author:BunivaTT,
pubmed-author:DogliottiLL,
pubmed-author:FasolisGG,
pubmed-author:FontanaDD,
pubmed-author:FrezzottiLL,
pubmed-author:PaganiGG,
pubmed-author:PallottiSS,
pubmed-author:RossettiS RSR,
pubmed-author:TarabuzziRR,
pubmed-author:ZolfanelliRR
|
| pubmed:issnType |
Print
|
| pubmed:volume |
84
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
39-44
|
| pubmed:dateRevised |
2008-12-12
|
| pubmed:meshHeading |
pubmed-meshheading:9619712-Aged,
pubmed-meshheading:9619712-Antibiotics, Antineoplastic,
pubmed-meshheading:9619712-Antineoplastic Agents, Hormonal,
pubmed-meshheading:9619712-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9619712-Bone Neoplasms,
pubmed-meshheading:9619712-Disease Progression,
pubmed-meshheading:9619712-Disease-Free Survival,
pubmed-meshheading:9619712-Goserelin,
pubmed-meshheading:9619712-Humans,
pubmed-meshheading:9619712-Male,
pubmed-meshheading:9619712-Middle Aged,
pubmed-meshheading:9619712-Mitomycin,
pubmed-meshheading:9619712-Neoplasms, Hormone-Dependent,
pubmed-meshheading:9619712-Prospective Studies,
pubmed-meshheading:9619712-Prostate-Specific Antigen,
pubmed-meshheading:9619712-Prostatic Neoplasms,
pubmed-meshheading:9619712-Survival Analysis,
pubmed-meshheading:9619712-Treatment Outcome
|
| pubmed:articleTitle |
Randomized comparison of goserelin acetate versus mitomycin C plus goserelin acetate in previously untreated prostate cancer patients with bone metastases.
|
| pubmed:affiliation |
Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Italy.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|